Microsoft word - pr bioa imm.doc
BioAlliance Pharma acquires the European commercialization
rights to pafuramidine for the treatment of
Pneumocystis carinii pneumonia
Building a consistent product portfolio in opportunistic infections in
cancer and AIDS patients
BioAlliance Pharma to host a conference call today at 11.30 AM CET
Paris time (10.30 AM GMT, London time)
Paris, December 5, 2007 – BioAlliance Pharma SA (Euronext Paris – ticker code BIO), today announced that it has entered into an exclusive licensing agreement with Immtech Pharmaceuticals Inc. (AMEX: IMM) covering the European commercialization rights to pafuramidine maleate. This patented, orally administered new chemical entity is currently in Phase III clinical trials in the USA for two indications: the treatment of Pneumocystis
Pneumonia (PCP) in AIDS patients and human African trypanosomiasis (also known as sleeping sickness). Pafuramidine has orphan designation in the United States. BioAlliance has also negotiated the grant of an option to sell pafuramidine in Europe for the prevention and treatment of malaria in travelers. In return, Immtech will receive an initial license fee of $3 million and up to an additional $13 million if pafuramidine achieves European regulatory approval and pricing milestones. Immtech will receive significant royalties on sales and may also earn two additional milestone payments linked to the turnover generated. Furthermore, if BioAlliance elects to exercise the option to commercialize pafuramidine for malaria prophylaxis, it will start to share the clinical development costs for a Phase III trial which is due to start shortly. Marketing approval in malaria will trigger the payment of additional regulatory, pricing and sales milestones to Immtech, plus royalties on sales. Dominique Costantini, Chief Executive Officer of BioAlliance, said, “We are very keen to gain access to pafuramidine and work closely with Immtech in order to make a significant impact on PCP, a very serious disease.
She added that "We are pursuing the European growth strategy presented at the time of our fund raising by private placement in July, with the acquisition of late-stage development products such as pafuramidine. The compound displays particularly valuable activity in resistant strains and constitutes
our first strategic acquisition – one that fits perfectly with our existing portfolio of
®, Doxorubicin Transdrug
®, and Acyclovir Lauriad
®, since all these products
are either already approved for marketing or in Phase III trials in oncology or infectious
PCP is a deadly fungal infection of the lungs and is the most common opportunistic
infection in people living with HIV (the virus that causes AIDS). The pathogen also
affects people whose immune system has been severely compromised by cancer
chemotherapy or immunosuppressive therapy following organ transplantation.
“We are delighted to be collaborating with BioAlliance on launching pafuramidine in
” commented Eric L. Sorkin, CEO and Chairman of Immtech Pharmaceutical Inc.
“With the recent European launch of Loramyc
®, in HIV or cancer patients, BioAlliance
has demonstrated its development expertise and marketing capabilities in this market.
The company's understanding of both patients and healthcare providers will be key to the
success of pafuramidine
Current treatment options for PCP include trimethoprim-sulfamethoxazole, primaquine
plus clindamycin, trimetrexate (with or without dapsone) plus leucovirin, atovaquone and
pentamidine. The risk of adverse events associated with the currently available treatment
options for PCP requires between 20-57% of all patients to be switched to better tolerated
regimens during their course of care.
The development of pafuramidine for the treatment of PCP was funded in part by a
National Cooperative Drug Discovery Groups grant from the National Institutes of
Health, Department of Health and Human Services, to the University of North Carolina at
Chapel Hill. Pafuramidine was initially synthesized at Georgia State University, a
member of Immtech’s Scientific Consortium. About BioAlliance Pharma
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic
infections in cancer and HIV. The company develops and commercializes innovative products which
address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and
the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In
addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral
herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted
release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug®
nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is
also developing a new therapeutic entities program focused on the oncology and HIV markets.
In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with
JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit
www.bioalliancepharma.com. About Immtech Pharmaceuticals, Inc
Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious
diseases. Immtech has advanced clinical programs that include new oral treatments for Pneumocystis
pneumonia (PCP), malaria and trypanosomiasis (African sleeping sickness) and has developed a well-
defined, expanding library of compounds targeting hepatitis C, fungal infections and bacterial infections.
Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for
products derived from a proprietary pharmaceutical platform. For additional information, please go to
http://www.immtechpharma.com Conference call:
Title: Conference call - BioAlliance Pharma announces the signature of an exclusive licensing
The slides will be available at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance
Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result of new information, future events or
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or
achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007
under the number R. 07-031, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance
Pharma S.A.'s website (http://www.bioalliancepharma.com).
For press releases and other company information, visit www.bioalliancepharma.com.
BioAlliance Pharma SA
FDA NEWS RELEASE For Immediate Release: July 17, 2012 FDA Approves Weight-Management Drug Qsymia The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or ad
ONLINE BANKING SAFETY (Tips to improve your protection while banking online ) Union Bank of India has gone to extraordinary lengths to ensure that your online transactions are secure, by placing its devises in most secured environment as evidenced by the digital certificate issued by “VERISIGN”. However, as a customer, if you follow few simple security practices as detailed below, i